New frontiers to cure Alport syndrome: *COL4A3* and *COL4A5* gene editing in podocyte-lineage cells

Sergio Daga1 · Francesco Donati2,3 · Katia Capitani2,3 · Susanna Croci1 · Rossella Tita4 · Annarita Giliberti1 · Floriana Valentino1 · Elisa Benetti1 · Chiara Fallerini1 · Francesca Niccheri2 · Margherita Baldassarri2 · Maria Antonietta Mencarelli4 · Elisa Frullanti1 · Simone Furini3 · Silvestro Giovanni Conticello2 · Alessandra Renieri1,4 · Anna Maria Pinto4

Received: 16 May 2019 / Revised: 9 October 2019 / Accepted: 13 October 2019 / Published online: 21 November 2019
© The Author(s) 2019. This article is published with open access

Abstract

Alport syndrome (AS) is an inherited genetic disorder characterized by range of alterations from glomerular basement membrane abnormalities up to end-stage renal disease. Pathogenic variants in the collagen α3, α4, and α5 encoding genes are causative both of the autosomal dominant and of the X-linked forms of AS. Podocytes are the only renal cells that are able to produce the COL(IV)α3-α4α5 heterotrimer. We have previously demonstrated how it is possible to isolate podocyte-lineage cells from urine of patients, providing an easily accessible cellular model closer to the podocytes’ physiological conditions. Taking advantage of disease-relevant cell lines, we employed a two-plasmid approach in order to achieve a beneficial and stable variant-specific correction using CRISPR/Cas9 genome editing. One plasmid carries a Donor DNA and a reporter system mCherry/GFP to track the activity of Cas9 in cells. The other plasmid carries a self-cleaving SpCas9 and the variant-specific sgRNA. We have analyzed two stable podocyte-lineage cell lines, harboring a variant in the X-linked *COL4A5* (p.(Gly624Asp)) and in the autosomal *COL4A3* gene (p.(Gly856Glu)). We have achieved reversion of variants greater than 40% with undesired insertions/deletions lower than 15%. Overall, we have demonstrated a new gene therapy approach directly on patients’ cells, key players of Alport pathogenesis, and we have reverted *COL4* causative variants towards the wild type state. These results, in combination with preclinical models, could open new frontiers in the management and the treatment of the disorder.

Introduction

Alport syndrome (AS) (OMIM# 301050) is a clinically heterogeneous nephropathy caused by pathogenic variants in collagen IV genes (*COL4A3* [MIM# 120070] [Ref Seq NM_000091.4], *COL4A4* [MIM# 120131] [Ref Seq NM_000092.4], *COL4A5* [MIM# 303630] [Ref Seq NM_000495.4]) with a prevalence of 1:5.000 despite a very high variability among the populations [1]. The collagen α3α4α5(IV) heterotrimer represents an essential constituent of the mature Glomerular Basement Membrane (GBM) and is only produced by podocytes [2]. Podocytes are the key cellular component of the glomerular structure and can be isolated from Alport syndrome patients’ urine samples [3]. Typically, the disease, restricted to COL4, is mainly characterized by a progressive ultrastructural damage of the GBM, which appears to be thickened and progressively delaminated. GBM disruption leads to severe clinical symptoms such as microhematuria, proteinuria, and an inexorable progression to End Stage Renal Disease (ESRD). Extrarenal manifestations, such as ocular (mono or bilateral hypoacusia) and visual manifestations (lenticonus and macular flecks) often worsen the clinical phenotype. The disease is genetically heterogeneous, but the majority of AS kindreds show X-linked semi-dominant inheritance, due to pathogenic variants in the *COL4A5* gene located in the Xq22 region. In this form, males are more...
severely affected than females and usually reach end-stage renal disease before the age of 30 [4–6]. Females manifest a slow progression of the disease in 12% of reported cases, and some may develop ESRD later in life. The COL4A3 gene, located in 2q36-37 head to head with COL4A4, is responsible for bothautosomal recessive and dominant forms of AS [7–9]. The existence of an ADAS form is still debated. However, in the past decade, it has been shown that ADAS accounts for a statistically significant proportion of cases [7]. Furthermore, the existence of ADAS as a mode of inheritance distinct from TBMN has been supported by the employment of a Next Generation Sequencing (NGS) approach in patients presenting with GBM alterations overlapping with the abnormalities found in the XLAS and the ARAS form. In these patients, a second causative pathogenic variant in COL4 genes has not been found. Recently, Pescucci et al. delineated the overall clinical picture of ADAS, which is characterized by hematuria and proteinuria evolving towards ESRD with a mean age of ESRD onset of 55 years [10].

Starting from a bacterial immune system, the Clustered Regularly-Interspaced-Short Palindromic Repeat (CRISPR/Cas9) system has developed into a gene editing approach that could provide therapy for many rare genetic disorders [11]. In the years, several Cas9 nuclease variants have been discovered and characterized [12, 13]. The most widely used Cas9 variant derives from Streptococcus Pyogenes (spCas9) [14]. The CRISPR/Cas9 system is composed of two elements: the single-guide RNA (sgRNA) and the endonuclease Cas9. The sgRNA is able to guide the Cas9 to the genomic site of action where a highly precise double strand break (DSB) has to occur [14] following a Watson–Crick base pairing recognition [15]. DSBs induced by CRISPR/Cas9 are usually resolved through Non-Homologous End Joining (NHEJ), which can lead to creation of deletions and insertions. However, the precision of the DSB correction can be increased by a ‘repair template’ Donor DNA complementary to the genomic region of interest that can be used to perform neo-synthesis of wild type DNA [14].

The success of the CRISPR/Cas9 system is tightly correlated with the ability to introduce both components into mammalian cells. The CRISPR/Cas9 system has been proven to be a particularly dynamic and versatile tool over the last few years, and has been shown to be efficient in correcting in vitro a wide range of rare genetic disorders [16–18].

The few available therapies are restricted to the use of Renin–Angiotensin–Aldosterone (ARBs) inhibitors which aim to delay the progression of clinical symptoms. Up to date, considering that the pharmacological treatments (ARBs, ACEi) appear to be only effective in delaying the progression of clinical symptoms, the most successful treatment remains kidney transplantation. Despite their successful application in many cases of ESRD, transplants also present some limitations. They are restricted by the availability of a compatible donor, and by the necessity of a life-long immunosuppressive treatment in order to avoid Graft versus Host Disease (GVHD). Building on the availability of AS patients urine-derived podocyte-lineage cells we show that a tailored CRISPR/Cas9 system is capable of efficiently correcting COL4 causative variants in the disease-relevant cell line. This opens up the possibility of a novel therapeutic approach for Alport syndrome cure.

Materials and methods

Patient’s selection

Diagnosis of AS was established at the Medical Genetics Unit in Siena (Azienda Ospedaliera Universitaria Senese, AOUS). Families underwent genetic counseling and blood samples were collected in EDTA containing tubes for COL4A3, COL4A4, and COL4A5 mutational analysis (next-generation sequencing and Sanger sequencing). Patients and healthy family members provided and signed a written informed consent at the Medical Genetics Unit of Azienda Ospedaliera Universitaria Senese, Siena, Italy for the use of DNA samples for diagnostic purposes and for urine samples collection with the purpose of isolating podocyte-lineage cells and characterizing intronic variants.

Patient 1 (1212/18ats): The patient is affected by the semi-dominant X-linked form of Alport syndrome. She is a 23 years old woman, and has presented with persistent microhematuria since the age of three. During her childhood episodic gross hematuria occurred, accompanied by upper respiratory tract infections. At the time of the most recent genetic counseling, proteinuria was absent and renal function preserved (creatinine: 0.6 mg/dL, eGFR: 127.6 mL/min). Audiological and ophthalmoscopic evaluations were reported as normal. Microhematuria and proteinuria were also reported in the father, who unfortunately was not available for genetic testing or counseling. NGS analysis performed on DNA from peripheral blood samples has revealed a COL4A5 [MIM# 303630] ([MIM# 303630] [Ref Seq NM_000495.4]) heterozygous variant c.1871G>A (p.(Gly624Asp)) which affects the function of the gene. This variant, localized inside the interruption of the collagenic domain, is reported in association with a milder phenotype in males with an X-linked form of the disease. Clinical data and variants were submitted to the Leiden Open Variation Database LOVD, www.lovd.nl/COL4A5 (Individual ID #00245760).

Patient 2 (3459/18ats): The patient is affected by the Autosomal Dominant form of Alport syndrome. She is a 41
year-old woman. She has presented with persistent microhematuria since age two, and developed proteinuria in her late thirties (1.6 g/24 h). A renal biopsy revealed GBM thinning and thickening. That combined with a lamina densa structure resulted in an Alport Syndrome diagnosis. Her audiological evaluation was normal, while ophthalmological evaluation showed astigmatism and myopia: both likely coincidental since they have not been previously reported as suggestive feature of AS. At the time of genetic counseling she was under therapy with Ramipril 10 mg/daily. Family history was suggestive of autosomal dominant AS. The younger brother, a 38-year-old male presented with microhematuria and proteinuria. He did not present with hematuria during infancy. Audiological and ophthalmoscopic evaluations were normal. The mother, a 71-year-old woman, reported the occurrence of microhematuria since age 32. Antihypertensive treatment was undertaken at the age of 68 to prevent progression to ESRD. Sensorineural hearing loss was detected by an audiological evaluation. NGS analysis revealed a COL4A3 ([MIM# 120070] [Ref Seq NM_000091.4]) heterozygous variant c.2567G>A (p.(Gly856Glu)) which affects gene function. The same variant was also detected in both the affected proband’s mother and brother. Clinical data and variants were submitted to the Leiden Open Variation Database LOVD, www.lovd.nl/COL4A3 (Individual ID #00245757).

Urinary isolation

Urinary samples from both patients one and two were processed within four hours of collection. Urine samples were centrifuged at 400 × g for 10 min. The pellet was washed with 10 ml of Washing Buffer and again centrifuged at 200 × g for 10 min. After the removal of the supernatant, the pellet was resuspended in 250 μl of DMEM/high glucose and Ham’s F12 Primary Medium and plated in gelatin treated culture dishes. Primary medium was added to the culture for the next three days (i.e., 24, 48, and 72 h after plating). Approximately 96 h after plating, one third of the medium was removed and 1 ml of RE/MC medium was added. The proliferation medium was changed daily, until two groups of small colonies were noticed: a first group of cells with a more regular appearance, smooth-edged contours, and cobblestone-like cell morphology, and a second group, more randomly arranged with a higher proliferation rate (Fig. 2a Upper Right Panel). Cells were split around 9–12 days after plating.

Preparation of the plasmids

Variant-specific sgRNAs were designed using the MIT CRISPR design tool (http://crispr.mit.edu). Both plasmids were cloned using a backbone from p.AAV2.1 obtained from TIGEM labs in Pozzuoli. The reporter plasmids were obtained by inserting the Human U6 promoter cassette for the expression of the sgRNA and the mCherry/GFP reporter system (Addgene #54322). Human U6 promoter was amplified by PCR using specific annealing primers (primers #1–2) from px330 (Feng Zhang’s Addgene plasmid #42230) with KOD Hot Start DNA Polymerase (Merck). The amplified product was cut and inserted into pAAV2.1, cutting the backbone using SacI and XhoI restriction enzymes at specific restriction sites. Oligonucleotides to create sgRNAs specific for the variants to target (#7–8/#9–10) were cloned after annealing and phosphorylation in the BpiI restriction site, under Human U6 promoter control. The mCherry/GFP reporter and the Donor DNA were synthesized (IDT, Coralville, Iowa, USA) and cloned into the U6 AAV vector in AflIII and SacI restriction sites. The Donor templates (#11, #12) used to drive the correction of the target sequences were designed with 50 nt homology arms flanking the nucleotide to be corrected.

The autocleaving Cas9 plasmids were obtained by cloning the CMV promoter filled-in the sticky ends with AB Pfu polymerase (AB Analitica into its proper backbone. The backbone was then phosphorylated and inserted into NheI and NotI restriction sites. Then, the spCas9 was amplified by PCR (target-containing primers #3–4/#5–6) with KOD Hot Start DNA Polymerase (Merck), and cut and inserted in BamHI and SacII sites, under the control of the CMV Promoter.

The Oligos used for the cloning are listed in Table 1. Plasmids sequences have been submitted to Addgene Vector Database (https://www.addgene.org) with these accession numbers: for COL4A3 Donor/Reporter (130279) and COL4A3 self-cleavingCas9 (130281) for COL4A5 Donor/Reporter (130280) and COL4A5 self-cleavingCas9 (130282), respectively.

Cell culture and transfections

HEK293T cells were cultured at 37 °C, 5% CO2, in Dulbecco’s modified eagle medium, (DMEM, EuroClone) supplemented with 10% fetal bovine serum (FBS; Carlo Erba), 2 mM l-glutamine (Carlo Erba), and 1 mM penicillin/streptomycin (Carlo Erba). Transient transfections were performed in 24-well plates using PEI (1 µg/µl) according to the manufacturer’s protocol. Hundred nanogram of reporter plasmid and 400 ng of Cas9 encoding plasmid were transfected. FACS analysis was performed 48 h after transfection.

Urine-derived podocyte-lineage cells were isolated from the urine of affected patients who harbor either a COL4A3 ([MIM# 120070] [Ref Seq NM_000091.4]) (c.2567G>A p. (Gly856Glu)) and a COL4A5 ([MIM# 303630] [Ref Seq NM_000495.4]) (c.1871G>A p.(Gly624Asp)) variant. 1 × 10⁶ cells were electroporated using the Neon® Transfection
System (Thermo Fisher Scientific®, Waltham, Massachusetts, United States) in accordance with manufacturer’s protocol. Ten microgram of Reporter and 15 µg of Cas9 were co-transfected using the Neon System (1.150 pulse voltage [V], 20 pulse width [ms], 2 pulse number) according to the manufacturer’s protocol.

Untransfected cell population was used as negative control sample and cells electroporated with eGFP encoding plasmid (pAAV2.1_CMV_eGFP3) [19] alone were used as transfection positive control.

After transfection, cells were plated on 60 mm plate coated with 0.1% human gelatin (Merck Millipore®, Burlington, Massachusetts, United States), using RE/MC growth medium without penicillin/streptomycin.

Isolation of mCherry(+)/GFP(+) single cells using fluorescent activated cell sorting (FACS)

Cells were analyzed and sorted on a fluorescent-activated cell sorter FACSAria IU using FACSDiva software version 8.0.1 (BD Biosciences). Cells were resuspended in PBS with a 2 mM EDTA. The cellular suspension was filtered through a 30 µm filter (BD Biosciences). The urine-derived podocyte-lineage cells were sorted using a 70 µm nozzle and an event rate of 10,000/s.

EGFP and mCherry positive cells were quantified using a Cytoflow cytometer with blue (488 nm) and a yellow (560 nm) lasers, with a 530/30 (EGFP) and a 585/42 (mCherry) filter.

DNA extraction

Total DNA was extracted from sorted cells using QIAMP DNA Micro Kit (QIAGEN®, Hilden, Germany) in accordance with manufacturer’s protocol. DNA from control cells was extracted starting from the same amount of cells. DNA was eluted into 25 µl of DNase Free Water.

The concentration of RNA was determined by using a Qubit2.0 Spectrophotometer (Thermo Fisher Scientific®, Waltham, Massachusetts, United States).

Ion torrent S5 sequencing

The Ion AmpliSeq 2.0 Library Kit (Life Technologies, Carlsbad, CA) was used for library preparation. The kit allowed us to obtain a barcoded library of 184 amplicons, corresponding to the 151 exons col COL4A3/COL4A4/ COL4A5 genes compatible with the ION S5 platform, according to the manufacturer’s protocol (https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0006735_AmpliSeq_DNA_RNA_LibPrep_UG.pdf).

Libraries were purified using Agencourt AMPure XP system and quantified using the Qubit® dsDNA HS Assay Kit reagent (Invitrogen Corporation, Life Technologies),
pooled at an equimolar ratio, annealed to carrier spheres (Ion Sphere Particles, Life Technologies) and clonally amplified by emulsion PCR (emPCR) using the Ion Chef system (Ion Chef, Life Technologies). Ion 510, 520, or 530 chips were loaded with the spheres carrying single stranded DNA templates and sequenced on the Ion Torrent S5 using the Ion S5 Sequencing kit, according to the manufacturer’s protocol.

Post-experiment analysis was conducted using the latest version (v5.8.0) of the data analysis software Torrent Suite (Life Technologies). A coverage assessment was performed using the ‘coverageAnalysis’ plug-in (v5.8.0.8) that gives information about the amplicon read coverage. Variants were called using the ‘variantCaller’ plug-in (v5.8.0.19).

Results
Editing strategy

Using the MIT CRISPR Design Tool, we selected a sgRNA that precisely targets the mutated \textit{COL4A3} and \textit{COL4A5} alleles (Fig. 1a). For the selected sgRNA an adjacent spCas9 PAM (N)GG is present on sense or antisense DNA strand. We have chosen to split the all-in-one plasmid into two distinctive plasmids, in a dual-vector approach, for contemporary delivery into the cells of the two components of CRISPR/Cas9 (Fig. 1b, c).

The Cas9 plasmid expresses the spCas9, under the control of the CMV promoter, and a targeting vector harboring variant-specific sgRNA, under the control of the Human U6 promoter. The Donor/Reporter plasmid contains a GFP coding sequence out of frame with an mCherry one. In between the coding sequences, there is a sequence target for the sgRNA. Induction of indels by Cas9 at the linker will place the GFP cds in frame with the mCherry and will cause the expression of an mCherry-GFP chimera, that will serve as a proxy to identify cells in which Cas9 has been active.

Moreover, in the Cas9 plasmid the variant-specific sgRNA with the PAM sequence has been cloned flanking the spCas9 itself, allowing Cas9 auto-cleaving and thus avoiding a prolonged expression in time and drastically reducing the off-targets cuts.

The mCherry/GFP reporter system includes a specific sequence, corresponding to the sgRNA + PAM, between the coding sequences (CDS) of two fluorescent proteins. When cells are transfected with the reporter plasmid alone, mCherry is transcribed, resulting in red fluorescence. In this...
condition GFP CDS is out-of-frame and it is not expressed. On the contrary when cells are co-transfected with the plasmid encoding spCas9, GFP expression is induced. Indeed, in this state, the sgRNA drives spCas9 to the sgRNA + PAM sequence between the two fluorescent proteins, and spCas9 cutting this sequence, reports GFP CDS in frame. As a consequence, an mCherry/GFP fusion protein is reconstituted and the two fluorescent proteins are co-expressed only in cells in which the spCas9 is active. Forty eight hours are necessary to induce mCherry and GFP expression, which is the time necessary for the spCas9 transcription and activation.

Specificity of the sgRNA for the mutated allele

The double mCherry/GFP reporter plasmid allows us to view the cells in which the variant-specific sequence has been targeted by spCas9. Based on the same strategy, we then assessed whether the sgRNAs were able to recognize the mutated target, by inserting the wild type sequence between the two-fluorescence protein CDS. HEK293T cells transfected with the Donor/Reporter plasmid and spCas9 encoding plasmid yield a mCherry\(^{(+)}\)/GFP\(^{(+)\}}\) population through FACS analysis after 48 h; the red fluorescence of co-transfected cells with the Donor/Reporter plasmid harboring the wild type sequence between mCherry and GFP, and spCas9 plasmid, marks the specificity of sgRNA only for the mutated target. Activation of spCas9 or not, depending on the co-transfection with Donor/Reporter plasmid mutated or wild type, is shown (Fig. 1d).

Mutated podocyte-lineage cells transfection and editing

To confirm the functionality of our strategy on urine-derived podocyte-lineage cells, (Fig. 2a, Bottom right panel) plasmids were tested by transient transfection.

Cells were transfected with the reporter plasmid alone, and also in combination with the plasmid encoding spCas9. Finally, they were analyzed by fluorescent microscopy after 48 h post-transfection. Urine-derived podocyte-lineage cells harboring a COL4A5 ([MIM# 303630] [Ref Seq NM_000495.4]) variant (p.(Gly624Asp)) were transfected with both plasmids, whilst fluorescence was quantified 48 h post-transfection by fluorescence microscopy (Fig. 2b) and FACS analysis (Fig. 2c). Cell transfected with Donor/Reporter plasmid alone expressed mCherry but not GFP. On the contrary, among cells co-transfected with Donor/Reporter and spCas9 plasmids, a sizeable cell population expressed mCherry (35.5%), with 7.6% of these expressing also GFP. This result indicates a proper double-plasmid activation and the presence of a double-marked population that can be effectively recovered by means of FACS Sorter.

Editing efficiency on mutated podocyte-lineage cells

To confirm the functionality of the system in AS podocyte-lineage cells we verified the correction of COL4 variants in patient-derived cells. Two stable podocyte cell lines carrying a specific variant in COL4A5 ([MIM# 303630] [Ref Seq NM_000495.4]) c.1871G>A (p.(Gly624Asp)) and COL4A3 ([MIM# 120070] [Ref Seq NM_000091.4]) c.2567G>A (p.(Gly856Glu)), respectively were transfected using our two-plasmid system harboring both a Cas9/sgRNA combination for a targeted dsDNA cut and a template Donor DNA for the neo-synthesis of a wild-type DNA fragment. The mCherry/GFP reporter was used to isolate cells where Cas9 had been active. Forty eight hours after transfection, cells were sorted to recover the doubly fluorescent ones (Red/Green). DNA was extracted and analyzed by deep sequencing.

For both the corrected variants, the IGV Visualization Software has been used to inspect both the snip out and the replacement of the mutated base and the indels events erroneously present in the neighboring sites.

FASTQ files from transfected and control samples were uploaded to the online analysis tool CasAnalyzer [20], in order to ascertain the percentage of Homology Directed Repair (HDR) achieved, considering a comparison range (R) of 15 nucleotides around the cut site.

Our system turned out to be extremely efficient (HDR of 58.8%) in reverting the causative variant in COL4A5 and reaching an efficiency of HDR equal to 44.2% for COL4A3 variant (Table 2). The results obtained from CasAnalyzer and IGV Software are reported in Fig. 3 for COL4A5 (Fig. 3a, b) and Fig. 4 for COL4A3 (Fig. 4a, b).

TP53 polymorphism characterization

It has recently been demonstrated that the reduced stability of TP53 ([MIM# 191170] [Ref Seq NM_000546.4]) increases the rate of homologous recombination [21]. Therefore, we decided to characterize the functional genotype of TP53. The genotype of our patients at this locus demonstrated a heterozygous state (Arg/Pro) in both of them (Table 3) likely suggesting that polymorphism had an impact in modulating HDR rate.

Discussion

Alport Syndrome is a clinically heterogeneous nephropathy caused by pathogenic variants in collagen IV genes. Today, no cure has been made available for this devastating disorder. Conventional pharmacological treatments have proved insufficient over the years, because they focus only on slowing down the development of clinical symptoms. The
only effective treatment remains renal transplant, albeit with contingent difficulties in obtaining a compatible donor and subsequent immunosuppressive drug therapies that worsen the patient’s lifestyle. In addition, renal transplantation does not have an impact on affected extra-renal organs such as the eyes and ears. In this scenario, gene therapy aiming to correct the defect at the DNA level could be envisaged as revolutionary solution for an otherwise untreatable disorder.

The CRISPR/Cas9 technology in the past years, has emerged as an efficient solution to revert disease-causative variants. Using CRISPR, Xie et al. generated functional red blood cell precursors, ready for transplantation, from the fibroblast-derived iPSCs of a patient homozygous for β-thalassemia [18]. Two independent studies used CRISPR/Cas9 to correct alleles causing Duchenne muscular dystrophy in patient-derived iPSCs, further differentiated into skeletal muscle cells [16]. Rabai et al. have used CRISPR to correct heterozygous variants in the DNM2 gene that causes the autosomal dominant form of centronuclear myopathies, a rare muscle disorder [22]. Bak and colleagues combined

**Fig. 2** Transfection efficacy in urine-derived podocyte-lineage cells. **a** Type I (Upper left panel) and Type II (Upper right panel) urinary cell colonies (arrowheads) at day 4. At day seven the isolated cells start to aggregate in egg shape conformation (Bottom left panel). On the eighth day, cells starts to have clonal expansion and they can splitted (Bottom right panel) Scale bars, 400μm. **b** Both plasmids were transfected on cells in clonal growth stage (Bottom panel) and mCherry and GFP fluorescence was observed in vivo through fluorescence microscope. **c** Representative FACS analysis of GFP expressing. Cells were transfected either with Donor/Reporter plasmid alone and sgRNA/Cas9 coupled with the Donor/Reporter plasmids. The cells were analyzed by FACS 48 h after transient transfection. The percentage of GFP + cells is indicated in the upper right quadrant (UR). At least three independent experiments were performed. The average population in the UR quadrant was 0.2% for Reporter alone; 21.7% for Cas9 + Donor/Reporter

---

**SPRINGER NATURE**
CRISPR/Cas9 technology with the use of rAAV6 to obtain a precise homologous recombination in human hematopoietic stem cells (HSCs) [23]. Ma et al. have performed the first CRISPR/Cas9 application in human preimplantation embryos, acting on MYBPC3 variant and obtaining a high homology-directed repair efficiency by activation of an endogenous, germline-specific DNA repair response [24].

Over the last few years, a few CRISPR/Cas9 gene therapy-based trials have begun. In September 2018 the University of Pennsylvania, started a clinical trial based on engineering of T-cells from patients, using CRISPR to delete endogenous TCR and PD-1 genes, giving the patients’ immune systems new tools to fight cancer cells (NCT03399448). Moreover, Vertex Pharmaceuticals Incorporated have proposed a phase 1/2 study to evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001 in subjects with severe sickle cell disease (NCT03745287). In February 2019, the University Hospital in Montpellier started to exploit epigenomic editing in Kabuki Syndrome as a therapeutic strategy to rescue the activity of MLL4 (NCT03855631).

| Patient | Mutation | Sample | Total reads | HDR frequency | Ins/dels frequency | Wild Type reads = G (%) | Mutated reads = A (%) |
|---------|----------|--------|-------------|---------------|-------------------|------------------------|----------------------|
| 1       | COL4A5   | Edited cells | 110          | 58.80%        | 10 (8.8%)          | 95 (86%)               | 14 (15%)             |
|         | c.1871G>A |        |             |               |                   |                        |                      |
|         | (p.(Gly624Asp)) |      |             |               |                   |                        |                      |
| 2       | COL4A3   | Edited cells | 467          | 44.20%        | 12 (10.4%)         | 307 (66%)              | 160 (34%)            |
|         | c.2567G>A |        |             |               |                   |                        |                      |
|         | (p.(Gly856Glu)) |      |             |               |                   |                        |                      |

Fig. 3 CasAnalyzer results on editing efficiency on COL4A5 podocyte-lineage cells. CasAnalyzer Tool operating on the CRISPR/Cas9 treated sample and control has reported a HDR of 58.8% in patients’ mutated podocyte-lineage cells. IGV Visualization Software for the variant shows how there is a substantial loss of heterozygosity with the restoration of the wild-type base, confirming the functionality of the system.
taking advantage of a combination of the self-renewal potential of mesenchymal stem cells (MSCs) with CRISPR/Cas9 technology.

The objective difficulty in testing the CRISPR/Cas9 system on podocytes (the key cells affected in AS pathology) has always been a limit for preliminary in vitro studies aimed at effectively defining the COL4 variant correction index. We have now gone beyond this technical limit, obtaining a cell population from the urine of affected patients in a completely non-invasive way [3]. This new cell population, the urine-derived podocyte-lineage cells, has provided us with an ad-hoc cellular model close to the natural podocytes physiological condition for each individual patient and each variant. Here, we have developed this novel tool to test two COL4 variants, namely c.1871G>A (p.(Gly624Asp)) and c.2567G>A (p.(Gly856Glu)), in COL4A5 and COL4A3 respectively, mimicking two of the most frequent forms of hereditary transmission of the disease (XLAS and ADAS).

Here we report the correction of two disease-causative variants using an innovative self-inactivating dual-plasmid system through which homologous repair is driven by Cas9 induced DNA damage and a dsDNA donor fragment. The correction, as calculated by the CasAnalyzer tool, is very high, ranging from 44 to 58% in the COL4A3 and COL4A5 genes. These results along with the very low percentage of indels (8.8% for COL4A5 and 10.4% for COL4A3) demonstrate that our strategy is highly efficient in inducing a dramatic genetic modification on the DNA. What is more: this approach is tailored to the specificity highlighted by the specificity experiments reported in Fig. 1d.

Furthermore, we hypothesized that the correction efficiency was also influenced by a functional polymorphism present in TP53 gene ([MIM# 191170] [Ref Seq

Table 3 (p.(Pro72Arg))

| Patient n (code) | Mutation          | Pro72Arg genotype |
|------------------|-------------------|-------------------|
| 1                | COL4A5 c.1871G>A (p.(Gly624Asp)) | Arg/Pro           |
| 2                | COL4A3 c.2567G>A (p.(Gly856Glu)) | Arg/Pro           |

Fig. 4 CasAnalyzer results on editing efficiency on COL4A3 podocyte-lineage cells. The CasAnalyzer Tool performed on the CRISPR/Cas9 treated sample and control has reported a HDR of 44.2% in patients’ mutated podocyte-lineage cells. IGV Visualization Software for this variant also exhibited the loss of heterozygosity with the restoration of the wt base in COL4A3 gene.
A podocyte reserve fraction is still present and can be eye is particularly suited to this treatment, given its isolated apoptotic processes and cell death. CRISPR/Cas9 gene therapy could be also proposed to treat visual and hearing difficulties. With the strong evidence that CRISPR/Cas9 system can efficiently target affected cells in vitro, testing the system on an in vivo model such as naturally occurring Navasota Dog (a COL4A5 model) would be possible. We are therefore strongly convinced that AS will become a treatable disorder in the near future by a gene editing CRISPR/Cas9-based approach.

Acknowledgements We would like first to thank AS patients and their families. The “Cell lines and DNA bank of Rett Syndrome, X-linked mental retardation and other genetic diseases”, the members of the Telethon Network of Genetic Biobanks (project no. GTB12001), funded by Telethon Italy, and by the EuroBioBank network, who provided us with specimens, plus the A.S.A.L. Onlus association, who also provided us with specimens. We also thank a donation in the name of ‘Graziano and Marco Laurini’ to AR. This work was supported by Regione Toscana, Bando FAS-Salute 2014 (CUP ID: 4042.16092014.066000054), and the research funding program by the Alport Syndrome Foundation (ASF), the Pedersen Family, and the Kidney Foundation of Canada (KFOC). This work is generated by the ERKnet (European Reference Network for Rare Kidney Diseases). The approach described in this work is covered by Italian patent application no.102018000020230.

Author contributions SD, KC, FD, SGC, AR, and AMP have made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, and have been involved in drafting the manuscript. RT, SGC, FN, CF, and AG has made substantial contributions to analysis and interpretation of data, and have been involved in drafting the manuscript. MAM, and AR have made substantial contributions to interpretation of data and clinical evaluation. All authors have been involved in drafting the manuscript and have given final approval of the version to be published. They agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The study was approved by Azienda Ospedaliera Universitaria Senese Ethics Committee, Prot Name IPSA, Prot n 12030_2017 on 12.18.2017.

Informed consent Informed consent was provided to the patients before urine-derived podocyte-lineage cell isolation.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hertz JM, Thomassen M, Storey H, Flinter F. Clinical utility gene card for; Alport syndrome. Eur J Hum Genet. 2012;20.

2. Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St John PL. Cellular origins of Type IV Collagen Networks in developing Glomeruli. J Am Soc Nephrol. 2009;20:1471–9.

3. Daga S, Baldassarri M, Lo Rizzo C, Fallarini C, Imperatore V, Longo I, et al. Urine derived podocytes lineage cells: a promising tool for precision medicine in Alport syndrome. Hum Mutat. 2018;39:302–14.

4. Renieri A, Bruttini M, Galli L, Zanelli P, Neri T, Rossetti S, et al. X-linked Alport syndrome: a SSCP-based mutation survey over all 51 exons of the COL4A5 gene. Am J Hum Genet. 1996;58:1192–204.

5. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol. 2000;11:649–57.

6. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol. 2003;14:2603–10.

7. Longo I, Porcedda P, Mari F, Giachino D, Meloni I, Deplano C, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int. 2002;61:1947–56.

8. Longo I, Scala E, Mari F, Caselli R, Pescucci C, Mencarelli MA, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transpl. 2006;21:665–71.

9. Artuso R, Fallarini C, Dosa L, Scionti F, Clementi M, Garosi G, et al. Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet. 2012;20:50–71.

10. Pescucci C, Mari F, Longo I, Viquiatz P, Caselli R, Scala E, et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int. 2004;65:1598–603.

11. Karginov FV & Hannon GJ. The CRISPR system: small RNA-guided defense in bacteria and archaea. Mol Cell. 2010;37:7–19.

12. Casini A, Olivieri M, Petris G, Montagna C, Reginato G, Maule G, et al. A highly specific SpCas9 variant is identified by in vivo screening in yeast. Nat Biotechnol. 2018;36:265–71.

13. Lee J, Jung MH, Jeong E, Lee JK. Using Sniper-Cas9 to minimize off-target effects of CRISPR-Cas9 without the loss of on-target activity via directed evolution. J Vis Exp. 2019;26.

14. Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Exp Opin Drug Deliv. 2018;15:905–13.

15. WareJonusc Z, Campbell JM, Martinez-Gálvez G, Gendron WAC, Barry MA, Harris PC, et al. Precision gene editing technology and applications in nephropathy. Nat Rev Nephrol. 2018;14:663–77.

16. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep. 2015;4:134–54.

17. Ousterout DG, Kabadi AM, Thakore PI, Wh Majors, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun. 2015;18:6244.

18. Xie F, Ye L, Chang JC, Beyer AL, Wang J, Muench MO, et al. Seamless gene correction of h-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyback. Genome Res. 2014;24:1526–33.

19. Auricchio A, O’Connor E, Hildinger M, Wilson JM. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther. 2001;4:372–4.

20. Park J, Lim K, Kim SJ, Bae S. Cas-analyzer: an online tool for assessing genome editing results using NGS data. Bioinformatics. 2017;33:286–8.

21. Haapaniemij E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24:927–30.

22. Rabai A, Reisser L, Reina-San-Martin B, Mamchaoui K, Cowling BS, Nicot AS, et al. Allele-specific CRISPR/Cas9 correction of a heterozygous DNMT2 mutation rescues centronuclear myopathy cell phenotypes. Mol Ther Nucleic Acids. 2019;16:246–56.

23. Bak RO, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc. 2018;13:358–76.

24. Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017;548:413–9.

25. Thomas M, Kalita A, Labrecque S, Din D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–100.

26. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108:196–9.

27. Suzuki K, Tsunekawa Y, Hernandez-Benitez R, Wu K, Zhu J, Zhang J, et al. Effective delivery of large genes to the retina by dual AAV vectors. Gene Ther. 2014;21:450

28. Ertl HCJ, High KA. Impact of AAV capsid-specific vectors. J Virol. 2010;84:10830–8.

29. Qi YF, Li QH, Shenoy V, Zingler M, Jun JY, Verma A, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017;548:413–9.

30. Thomas M, Kalita A, Labrecque S, Din D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–100.

31. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108:196–9.

32. Suzuki K, Tsunekawa Y, Hernandez-Benitez R, Wu K, Zhu J, Kim EJ, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature. 2016;540:144–9.

33. Ertl HCJ, High KA. Impact of AAV capsid-specific T-cell response on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy. Hum Gene Ther. 2017;6:1574–83.

34. Qi YF, Li QH, Shenoy V, Zingler M, Jun JY, Verma A, et al. Correction of the transduction efficiency of tyrosine-mutant adeno-associated virus serotype vectors in kidney. Clin Exp Pharm Physiol. 2013;40:53–5.

35. Coletta P, Trapani I, Cesì G, Sommella A, Manfredi A, Pappo A, et al. Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther. 2014;21:450–6.

36. Trapani I, Coletta P, Sommella A, Iodice C, Cesì G, de Simone S, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO J. 2014;6:219–21.